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Objective: Many studies have been published regarding the influence of smoking on the incidence and prevalence of
peripheral arterial disease (PAD). A systematic review was performed to establish the magnitude of the effect of smoking
on the development of PAD, and a possible dose-response relationship.
Methods: English-language articles were reviewed by 2 observers using a standardized form, and were summarized in
tabular form. Data were extracted by 2 independent observers. Where possible, outcome data, expressed in terms of
prevalence or incidence, were recalculated as odds ratio or relative risk, with never-smokers as the reference group, or if
this was not available the nonsmoker group. Most studies did not provide primary data. Therefore the weighted means
were reported as a summary estimate, provided that a funnel plot between sample size and observed effect size made
publication bias unlikely.
Results: Sixteen articles describing 17 studies were included in the analysis. Four of the studies were prospective, and 13
were cross-sectional. The prevalence of symptomatic PAD was increased 2.3-fold in current smokers. Even in former
smokers the prevalence was substantially increased by a factor of 2.6. A clear dose-response relationship, with a strong
increase in risk for PAD in heavy smokers was observed. In countries where approximately 30% of the population are
smokers, 50% of PAD can be attributed to smoking.
Conclusions: Smoking is a potent risk factor for symptomatic PAD, with an important and consistent dose-response
relationship. With the persistence of high risk for PAD in former smokers, tobacco control programs should continue to
advocate smoking cessation, but focus even more on preventing future generations from ever starting to smoke. (J Vasc
Surg 2004;40:1158-65.)According to World Health Organization (WHO) es-
timates, there are currently 1.1 billion tobacco smokers
worldwide. This is about a third of the world population
aged 15 years and older. Recently, smoking-related death
has been upwardly adjusted to 4.9 million persons per
year.1
Tobacco use is considered the most important prevent-
able vascular risk factor for peripheral arterial disease (PAD)
inmen and women.2 The association between smoking and
PAD is even stronger than that between smoking and
coronary heart disease.3 The diagnosis of PAD is made a
decade earlier in smokers than in nonsmokers.3 In addition,
the amputation rate in patients with PAD who smoke is
twice that in persons who have never smoked.3
The relationship between smoking and PAD has
been recognized since 1911, when Erb reported that
intermittent claudication was 3 times more common in
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1158smokers and 6 times more common in heavy smokers,
compared with nonsmokers.4 Since then numerous stud-
ies have been performed on the relationship between
smoking and the incidence and prevalence of PAD. We
performed a systematic review to establish the so far
unknown magnitude of the effect of smoking on devel-
opment of symptomatic PAD, and if possible to deter-
mine a dose-response relationship.
METHODS
Search strategy and selection criteria. A search of
English, French, Dutch, and German medical articles and
reviews related to the influence of smoking on the inci-
dence and prevalence of symptomatic PAD was made with
MEDLINE, SUMsearch, Cochrane Library, and Pubmed
for the period from 1970 to the end of 2002. In addition,
a manual search of reference lists for relevant articles was
conducted. Search terms, using MeSH and free text, in-
cluded peripheral arterial disease, peripheral vascular dis-
ease, claudication, smoking, smoking cessation, nicotine,
incidence, prevalence, and risk factors.
Studies considered for inclusion met the following
criteria: (1) they evaluated the influence of smoking on the
incidence and prevalence of symptomatic PAD; (2) the
diagnosis of PAD was made with the ankle-brachial index,
Rose questionnaire or the WHO questionnaire, or at il-
iofemoral angiography. The Rose and WHO question-
naires have been widely used in epidemiologic surveys to
determine the presence of PAD. The questionnaires consist
of short questions on pain location and duration, and
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in low in comparison with noninvasive tests for PAD, which
is to be expected because in most patients PAD is asymp-
tomatic. In epidemiologic surveys the large amount of
included patients often leave no other option than use of
these surveys, with known underestimation of the presence
Table I. Characteristics of 17 included studies
No. of
subjects Contr Sex
Age
(y)
Method of
diagnosis
Prospective studies
Ingolfsson
et al11
8045 M 34-80 Questionnaire
Price
et al19
1592 M/F 55-74 Questionnaire
Hooi
et al10
2327 M/F 39 ABI,
questionnaire
Murabito
et al15
5209 M/F 28-62 Questionnaire
Cross-sectional studies
Cole
et al5
102 99 M — ABI,
angiography
Drexel
et al6
102 100 M/F 51-73 Angiography
Fowkes
et al7
418 1080 M/F 55-74 ABI,
questionnaire
Fowkes
et al8
167 1369 M/F 55-74 ABI,
questionnaire
Fowler
et al9
744 3726 M 65-83 ABI,
questionnaire
Ingolfsson
et al11
96 9045 M 34-80 Questionnaire
Lee
et al12
617 722 M/F 55-74 Questionnaire,
ABI
Leng
et al13
131 722 M/F 55-74 Questionnaire
Lowe
et al14
45 1096 M/F 55-74 ABI,
questionnaire
Ness
et al16
184 1727 M/F 72-89 ABI
Planas17 61 512 M 55-74 ABI
Powell18 291 828 M/F 56-71 ABI,
questionnaire
Smith20 147 18066 M 40-64 Questionnaire
ABI, Ankle-brachial index; CHb, Carboxyhemoglobin.of PAD.Studies were excluded on the basis of the following
criteria: (1) the data on PAD in smokers and nonsmokers
had not been separated; (2) the data on symptomatic and
asymptomatic PAD had not been separated; (3) additional
medication had been added to the study protocol.
Data extraction. The identification of studies was per-
king status Smoking intensity
Means of
smoking
Smoking
assessment
rent,
rmer,
ver
Light : 1-14
Moderate:15-24
Heavy : 25
Cigarettes,
pipe,
cigars
Questionnaire
rent, never Moderate: 25 pack-
years;
Heavy: 25 pack-
years
Cigarettes Questionnaire,
thiocyanate
rent,
rmer,
ver
Current, former, never Cigarettes Questionnaire
rent,
nsmoker
Cigarettes/day Cigarettes Questionnaire
rent,
rmer,
ver
Light: 1-20
Moderate: 20-40
Heavy: 40
Cigarettes Questionnaire,
plasma
cotinine
rent,
nsmoker
Pack-years Cigarettes Questionnaire
rent,
rmer,
ver
Current, former, never Cigarettes,
pipe,
cigars
Questionnaire
rent,
rmer,
ver
Current, former, never Cigarettes Questionnaire
rent,
rmer,
ver
Light: 1-14
Moderate: 15-24
Heavy: 25
Cigarettes Questionnaire
rent,
rmer,
ver
Light: 1-14
Moderate: 15-24
Heavy: 25
Cigarettes,
pipe,
cigars
Questionnaire
rent,
rmer,
ver
Pack-years Cigarettes Questionnaire
rent,
rmer,
ver
Pack-years Cigarettes Questionnaire,
thiocyanate
rent,
rmer,
ver
Pack-years Cigarettes Questionnaire,
thiocyanate
rent,
nsmoker
Current, nonsmoker Cigarettes Questionnaire
rent,
nsmoker
Pack-years Cigarettes Questionnaire
rent Pack-years,
Cigarettes/day
Cigarettes,
pipe,
cigars
Questionnaire,
thiocyanate,
CHb,
plasma
cotinine
rent,
rmer,
ver
Cigarettes/day Cigarettes,
pipe,
cigars
QuestionnaireSmo
Cur
fo
ne
Cur
Cur
fo
ne
Cur
no
Cur
fo
ne
Cur
no
Cur
fo
ne
Cur
fo
ne
Cur
fo
ne
Cur
fo
ne
Cur
fo
ne
Cur
fo
ne
Cur
fo
ne
Cur
no
Cur
no
Cur
Cur
fo
neformed by 1 reviewer (E.M.W.), and was checked for
; OR,
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authors (M.H.P.). Data from the studies included in the
survey were extracted by 2 independent observers
(E.M.W., M.H.P.) using a standardized form, and were
summarized in tabular format. Disagreements were re-
solved by discussion, and the final results were included in
the review. Since the objective was to obtain a quantitative
estimate of the effect size and dose-response relationship
for the influence of smoking on symptomatic PAD, results
adjusted for the effects of other risk factors for PAD were
included in the final summary. This summary was on the
difference in incidence or prevalence of PAD between
current smokers, former smokers, never-smokers, and non-
smokers (where no differentiation was made between
never-smokers and former smokers), and smoking inten-
sity.
Data analysis. When possible, outcome data, ex-
pressed in terms of prevalence or incidence, were recalcu-
lated as odds ratio or relative risk, with never-smokers as the
reference group, or if this was not available the nonsmokers
group. Odds ratios are used in cross-sectional studies, and
describe the ratio of the probability of PAD in smokers
divided by the probability of PAD in nonsmokers. Relative
risk is used in prospective studies to describe the ratio of the
risk for development of PAD in smokers divided by the risk
for development of PAD in nonsmokers. Inasmuch as,
retrospectively, most studies did not provide the primary
data (number exposed, years of exposure, number of out-
come events) or confidence intervals, an alternative method
was sought to provide summary estimates. To this end, an
assessment was made if a publication bias was present, using
a standard funnel plot. The performed funnel plots are
scatter plots of the effect of smoking on the development of
PAD on the x-axis against the study sample size on the
y-axis. The effect estimates from small studies will therefore
scatter more widely at the bottom of the graph, with the
spread narrowing among larger studies. In the absence of a
publication bias the plot should resemble a symmetric
inverted funnel. In the absence of bias, the weighted mean
was calculated with the number of patients as the weight
Table II. Effect of current smoking on prevalence of PAD
Reference Smoking description
Hooi et al10 Current smoker, PAD
Former smoker, PAD
Ingolfsson et al11 1-14 cigarettes/day
15-24 cigarettes/day
25 cigarettes/day
Pipe or cigars
Former smoker
Murabito et al15 Per 10 cigarettes/day
Price et al19 25 pack-years
25 pack-years
pack-years
PAD, Peripheral artery disease; NP, value not provided; NS, not significantfactor.RESULTS
The literature search resulted in identification of 20
potentially eligible articles.5-24 Of these, 4 articles had to be
excluded, either because no incidence or prevalence data
were available or because no differentiation had been made
between symptomatic and asymptomatic PAD and other
atherosclerotic diseases.21-24 Of the remaining articles, 3
described prospective data and 12 others described cross-
sectional data.5-10,12-20 One other article described both
prospective and cross-sectional data.11One prospective and
4 cross-sectional articles referred to the Edinburgh Artery
Study, but described in the majority of cases different
(sub)populations or outcomes.7,8,13,14,19 In case of multi-
ple results of the Edinburgh Artery Study on a single
outcome, the study with the largest number of patients was
included in the relevant analysis.
Sixteen articles describing 17 studies satisfied the inclu-
sion and exclusion criteria, and therefore were included in
the analysis.5-20No systematic reviews were identified. De-
tails of the articles included are summarized in the Table I.
Definitions. Most studies included in the survey con-
firmed the PAD diagnosis on the basis of the ankle-brachial
index, whereas 6 studies used either the Rose claudication
questionnaire or the WHO claudication questionnaire, and
another 2 studies used (additional) angiography (Table I).
All studies evaluated the effects of cigarette smoking; pipe
and cigar smoking was added to the analysis in 1 prospec-
tive and 4 cross-sectional studies. Duration of smoking was
reported as never-smoker, former smoker, nonsmoker, and
current smoker. For former smokers the duration of cessa-
tion was registered in 1 study. The intensity of smoking was
predominantly recorded in terms of pack-years (number of
cigarette packs a day multiplied by number of smoking
years) or in different classes. Classes varied from number of
cigarettes a day to never-smoker, former smoker, or current
smoker.
Incidence of PAD in current smokers. The 4 pro-
spective studies describing the incidence of PAD are sum-
marized in Table II. Two prospective studies provided odds
ratios rather than hazard ratios.10,15 One provided odds
rospective studies
Symptomatic PAD P
OR, 4.3; 95% CI, 1.9-10.1 NP
OR, 1.4; 95% CI, 0.5-3.7 NS
RR, 2.6 .001
RR, 7.7 .001
RR, 10.2 .01
RR, 3.6 .001
RR, 2.3 NS
OR, 1.4; 95% CI, 1.3-1.5 .0001
RR, 1.87; 95% CI, 0.9-3.9 .001
RR, 3.94; 95% CI, 2.0-7.6 .001
Mean  SD, 4.46  0.35 .001
odds ratio; CI, confidence interval; RR, relative risk.in pratios for the incidence of PAD in smokers, and the second
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scribed the increasing incidence of PAD in smokers as a
function of pack-years without discriminating between cur-
rent smokers and former smokers.19All studies showed that
the risk for development of symptomatic PAD increased in
smokers. Since all 4 studies used different categories to
define current smoking, the data could not be used for an
overall effect size of smoking on the incidence of PAD.
Prevalence of PAD in current smokers. The studies
all showed a significant increase in PAD in current smokers
(Table III). Three studies of the Edinburgh Artery Study
reported on this subject, and therefore only 1 study has
been used for the summary analysis.7 The funnel plot gave
no indication for the presence of a publication bias (Fig 1).
The weighted mean for the overall odds ratios for symp-
tomatic PAD in current smokers was 2.3. One study deter-
mined the risk for male and female subjects, and showed a
higher prevalence in female smokers.18 In 1 study the age at
onset of smoking was taken into account, with a significant
increase in risk when a person started smoking at age 16
years or younger.17 Powell et al18 analyzed the effect of
low-tar cigarettes in reducing risk for PAD development,
but found no evidence that these cigarettes are less harmful.
And finally, 4 prospective studies analyzed the influence of
pipe and cigar smoking. One of these studies found com-
parable odds ratios between cigarettes and pipe or cigar
smoking, and the remaining studies did not present sepa-
rate data on pipe and cigar smoking in their analy-
sis.7,11,18,20
PAD in relation to smoking exposure. The smoking
dose-response relationship was evaluated in 2 prospective
studies (Table II) and 8 cross-sectional studies (Table IV).
The prospective studies that assessed the relationship be-
tween smoking dose response and PAD found a statistically
significant exposure associated with an increase in PAD
incidence.11,15,19 One study determined the incidence of
symptomatic PAD in relation to smoking exposure, with an
increase from 2.6% in never-smokers to 9.8% in heavy
Table III. Effect of current smoking on prevalence of PA
Reference Smoking description
Drexel et al6 Overall (30 pack-years)
Fowkes et al7 Overall
Fowkes et al8* Overall
Fowler et al9 Overall
Ingolfssen et al11 Pipe or cigars
Lee et al12 Overall
Lowe et al14* Overall
Ness et al16 Male smokers
Female smokers
Smith et al20 Overall
Planas et al17 Start at age 17 years
PAD, Peripheral artery disease; OR, odds ratio; CI, confidence interval; NP
*Edinburgh Artery Study; not included in weighted mean calculation.smokers.19In six of the 8 cross-sectional studies a clear dose-
response relationship was observed.5,7,9,13,14,18 In the re-
maining 2 studies an identical picture of increasing odds
cross-sectional studies
Symptomatic PAD
POR 95% CI
1.7 1.2-2.5 NP
3.7 1.7-8.0 .001
2.7 NP
3.9 2.9-5.1 NP
7.4 NP
2 NP
2.4 1.3-4.4 NP
2.6 NP
4.6 NP
1.8 .009
3.3 NP
e not provided.
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Fig 1. Funnel plot of cross-sectional studies of smokers versus
nonsmokers. Effect of smoking on development of peripheral
artery disease is represented on the x-axis; study sample size is
represented on the y-axis. Funnel-shaped lines represent 95% con-
fidence interval around estimated effect size. OR, Odds ratio.D in
, valuratios with number of cigarettes smoked per day was seen,
, valu
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rettes per day).11,18
PAD in former smokers. Two prospective studies
(Table II) and 9 cross-sectional studies (Table V) divided
the nonsmoker group into never-smokers and former
smokers. In the prospective studies an increase in risk for
PAD in former smokers was present, but was not significant
in either study.10,11
In 1 cross-sectional study the odds ratios correlated
Table IV. Presence of smoking dose-response relationship
Reference Smoking description
Cole et al5 1-20 cigarettes/day
41 cigarettes/day
Fowler et al9 1-14 cigarettes/day
15-24 cigarettes/day
25 cigarettes/day
Ingolofsen et al11 1-14 cigarettes/day
15-24 cigarettes/day
25 cigarettes/day
Powell et al18 1-14 cigarettes/day
15-24 cigarettes/day
25 cigarettes/day
Leng et al13 25 pack-years
25 pack-years
Lowe et al14 Pack-years 1
Fowkes et al7 Pack-years
Cole et al5 11 pack-years
22 pack-years
33 pack-years
44 pack-years
44 pack-years
Powell et al18 31 pack-years
31-49 pack-years
49 pack-years
PAD, Peripheral artery disease; OR, odds ratio; CI, confidence interval; NP
Table V. Difference between development of PAD in form
sectional studies
Reference Smoking description
Cole et al5 Overall
Fowler et al9 Overall
Fowkes et al7 Cessation 5 years
Fowkes et al8* Overall
Ingolofsen et al11 Overall
Lee et al12 Overall
Leng et al13 25 pack-years before cessa
25 pack-years before cessa
Lowe14* Cessation  5 years
Cessation duration (y)
Fowler et al9 1
1-4
5-9
10-19
20
OR, Odds ratio; CI, confidence interval; NP, value not provided.
*Edinburgh Artery Study; not included in weighted mean calculation.with the severity of PAD.7A dose-response relationshipbefore cessation was seen, with an odds ratio of 3.6 in
subjects who smoked for less than 25 pack-years, and 4.8 in
those who smoked 25 or more pack-years.13 One study
took the duration of cessation into account, with odds
ratios ranging from 5.4 in subjects who had stopped smok-
ing less than 1 year previously, down to 1.3 in those who
stopped smoking more than 20 years before.9
The overall relative risks and odds ratios for symptom-
atic PAD in former smokers are summarized in Fig 2. The
prevalence of PAD
Symptomatic PAD
POR 95% CI
8.3 NP
15.0 NP
3.9 2.7-5.6 NP
6.6 4.2-10.5 NP
7.3 4.2-12.8 NP
10.7 NP
13.9 NP
8.1 NP
1.0 .522
1.4 1.0-2.1 .522
1.1 0.7-1.6 .522
3.6 NP
5.9 NP
1.3 1.2-1.5 NP
1.1 1.0-1.3 .001
2.3 NP
4.1 NP
8.8 NP
10.8 NP
12.9 NP
1.0 0.011
1.23 0.84-1.79 0.011
1.63 1.11-2.39 0.011
e not provided.
mokers and never-smokers in prospective and cross-
Symptomatic PAD
POR 95% CI
2.3 NP
2.1 1.6-2.6 NP
3.0 1.5-6.3 NP
2.1 NP
3.5 NP
1.9 NP
3.6 NP
4.8 NP
4.3 2.0-9.2 NP
5.4 2.4-11.9 NP
3.8 2.5-5.7 NP
3.7 2.5-5.7 NP
2.7 2.0-3.6 NP
1.3 1.0-1.7 NPforer s
tion
tionfunnel plot gave no indication of the presence of a publica-
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ratios for symptomatic PAD in former smokers was 2.6.
The prevalence of symptomatic PAD in former smokers
decreased in every study when compared with current
smokers, but nevertheless was still closer to the status of
current smokers than to never-smokers.
Additional observations. Three cross-sectional stud-
ies showed that smokers in whom PAD develops have a
higher pack-year level than do smokers in whom PAD does
not develop, with an average number of pack-years of
37.7 for PAD versus 17.9 for smokers without
PAD.6,12,17Consistent with these findings, a dose-response
relationship was observed, with 23 pack-years for smokers
without PAD compared with 25 pack-years for patients
with minor asymptomatic PAD, 32 pack-years for those
withmajor asymptomatic PAD, and 36 pack-years for those
with symptomatic PAD.7
The reported relative risks for cigarette smoking were
higher for PAD than for coronary artery disease.19 Age-
adjusted and sex-adjusted relative risk for PAD associated
with smoking was 1.9 for moderate smokers and 3.9 for
heavy smokers. Similarly adjusted risk for coronary artery
disease was 1.6 and 1.7, respectively.19
DISCUSSION
PAD in smokers. All studies that qualified for our
review showed an increase in risk for symptomatic PAD in
current and former smokers. The increase observed in the
prevalence of symptomatic PAD in smokers was 2.2. This
indicates that in countries where approximately 30% of the
population smokes, 50% of PAD can be attributed to
smoking. This population attributable risk is substantially
higher than for smoking on coronary heart disease deaths
(30%).25 There was continued increase in risk in former
smokers. Of interest, a clear dose-response relationship
between smoking and risk for PAD was observed.
Limitations of this review. The inability of some
older studies to comply with the applied inclusion criteria
with respect to PAD diagnosis resulted in exclusion of these
studies. In the remaining studies a large variety of outcome
measurements showed little similarity in the definitions
used for PAD diagnosis, duration of smoking, and intensity
of smoking.
Most articles provided cross-sectional data, which is a
serious source of bias, especially with respect to assessment
of tobacco exposure. However, if the number of cigarettes
smoked per day was substantially underestimated, this
would imply that the actual dose-response relationship was
more pronounced. Furthermore, the decrease in dose-
response relationship in the heavy smoker group could
imply that those patients died from other smoking-related
diseases.
The Edinburgh Artery Study, with 1 prospective study
and 4 cross-sectional studies included, was overrepre-
sented. Therefore multiple studies of the same analysis have
been excluded, taking only 1 study into account.
Most studies evaluated the influence of smoking as an
item among many different risk factors. However, crudeand adjusted effected size of smoking was similar. Raw data
were often not available, which resulted in inability to
perform a classic meta-analysis. Although confidence inter-
vals could not be calculated, most individual studies indi-
cated that their results were already statistically significant.
Hence we believe that our summary effect estimates will
have confidence intervals that are highly significant. To
provide an alternative best estimate of effect size, the
weighted mean was calculated. Despite the limitations of
the individual studies, the data represented gave a consis-
tent description of the influence of smoking.
Implications. Without doubt, the best method for
limiting the risk for development of atherosclerotic and
other smoking-related diseases is to not start smoking in
the first place. The prevalence of smoking has decreased
considerably over the last decades, from approximately 50%
in the mid-1960s to 30% at the present time.26 On the
down side, however, is the increase in smoking in young
adults, on whom anti-smoking campaigns seem to have
1,4
2,3
2,3
2,1
3,5
1,9
0
2000
4000
6000
8000
10000
0,1 1 10
OR estimate
S
a
m
p
le
 S
iz
e
Fig 2. Funnel plot of prospective and cross-sectional studies of
former smokers versus nonsmokers. Effect of former smoking on
development of peripheral artery disease is represented on the
x-axis; study sample size is represented on the y-axis. Funnel-
shaped lines represent 95% confidence interval around estimated
effect size. OR, Odds ratio.little effect.27When taking into account that the prevalence
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years, the limited effect of anti-smoking campaigns for
teenagers is a serious cause for concern.17
The gender gap between male and female smokers has
narrowed considerably over the last 3 decades, but despite
women still smoking less, they are at higher risk for PAD
than their male counterparts. This higher susceptibility to
the effects of smoking is analogous with the risk for lung
cancer, and evidence is growing for increased risk for myo-
cardial infarction.28,29
The rapid reduction in risk after smoking cessation, as
has been shown in the development of coronary heart
disease and stroke, seems deficient with respect to
PAD.30,31 Furthermore, patients with PAD seem to be less
successful in smoking cessation than patients after myocar-
dial infarction, with success rates of only 11% for PAD
compared with 50% in patients after myocardial infarc-
tion.32,33 Only after a substantial period of smoking cessa-
tion, which is correlated with smoking exposure, was a
reduction in risk for development of symptomatic PAD
apparent.
Smokers who do not to stop often replace normal
cigarettes with low-tar cigarettes or cigars. However, a
reduction in risk as a result of smoking low-tar cigarettes
has not been provided. In 2 studies the effect of cigar
smoking was comparable to that of cigarette smoking, but
in general the data on the risk-reducing influence of cigars,
pipes, and low-tar cigarettes are too few to draw firm
conclusions.11 In addition to this replacement strategy,
reduction (ie, cutting down on the number of cigarettes
smoked per day) is a common strategy used by smokers to
reduce harm. Although a dose-response relationship for
smoking in PAD was present and has been reported in
other atherosclerotic diseases, such as stroke and coronary
heart disease, no evidence exits that major health risks are
reduced with this stategy.20,33The presence of a dose-
response relationship, that is, persons who smoke less are at
reduced excess risk, does not imply that heavy smokers who
reduce the number of cigarettes smoked acquire the same
reduced risk. Furthermore, smoking is primarily a nicotine-
seeking behavior, and smokers who reduce the number of
cigarettes smoked tend to compensate by taking more and
deeper puffs from each cigarette and smoking more of it.34
This results in a much smaller proportional reduction in
intake of nicotine, and associated tar and other toxins, than
the reduction in number of cigarettes suggests.34
CONCLUSION
This review shows a considerable increased risk for
symptomatic PAD due to smoking. This risk was substan-
tial and consistent, with a clear dose-response relationship.
Adverse effects were even more pronounced in female
smokers and persons who started smoking before age 16
years.Many adverse health effects of smoking are reversible,
but the risk for developing PAD seems to persist, in con-
trast to the rapidly decreasing risk for myocardial infarction
and stroke. With the persistence of high risk in former
smokers, tobacco control programs should continue toadvocate smoking cessation. However, even more effort
should be put into preventing new generations from start-
ing to smoke.
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